



Genzyme Corporation  
500 Kendall Street  
Cambridge, MA 02142  
www.genzyme.com

**For Immediate Release**  
July 15, 2004

Media Contact:  
Maria Foley  
(617) 768-6690

**Genzyme Extends Humanitarian Partnership with Project HOPE**  
-----  
**Gaucher Initiative Serving Patients Around the World**

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) and Project HOPE, an international, nonprofit, health education and humanitarian assistance organization, today announced that they have extended their innovative partnership to provide enzyme replacement therapy to Gaucher patients around the world.

Since its creation in 1999, more than 200 patients in 17 countries, many of them children with severe Gaucher disease, a rare inherited disorder, have received Genzyme's life-saving therapy, Cerezyme® (imiglucerase for injection), through the Gaucher Initiative project. The new partnership agreement announced today provides continuation of the program for another five years, ensuring that Gaucher patients around the world will continue to have access to this therapy, regardless of their access to reimbursement from insurance providers or government authorities. In countries where Project HOPE does not operate, Genzyme has several additional programs that work with other healthcare organizations and patient groups to provide access to therapy.



“This is our responsibility and our obligation to patients,” said Henri Termeer, chairman and chief executive officer of Genzyme Corporation. “Biotechnology exists to create medical breakthroughs for unsolved medical problems, and the challenge is to make these treatments available to people in need all over the world. This is exactly what the Gaucher Initiative has accomplished in its first five years, and I am very pleased that we will continue to work with Project HOPE for another five years to make certain that those in need of treatment receive it.”

The Gaucher Initiative is a first-of-its-kind partnership between a biotechnology company and a non-profit organization, and is intended for patients with severe or life-threatening Gaucher disease. The program provides Gaucher patients living in developing countries of the world access to Cerezyme, the standard of care for the treatment of Type 1 Gaucher disease. Cerezyme was developed and commercialized by Genzyme. It manages and reverses many of the signs and symptoms of Gaucher disease, a rare inherited lysosomal storage disorder.

Genzyme donates Cerezyme to Project HOPE through the Gaucher Initiative and provides financial support to administer the program. Project HOPE is responsible for delivering the drug to its destination through its international infrastructure, and for monitoring tracking, patient compliance, and physician and governmental education. Genzyme and Project HOPE have trained hundreds of physicians to establish local treatment programs.

“There are now more than 200 patients around the world, living and thriving because of this important program,” stated John Howe III, M.D., president and chief executive officer of Project HOPE. “Project HOPE is proud to have a partner like



Genzyme that is dedicated to making a positive difference for these patients and very happy to know that we will continue to work together in this important effort.”

“The challenge is to make responsible, culturally sensitive, medical decisions to promote the health of families affected by Gaucher disease,” said Greg Grabowski, M.D., director of Human Genetics at Cincinnati Children’s Hospital Medical Center and chairman of the Gaucher Initiative’s Expert Medical Committee, a panel of six internationally respected physicians who determine patient need and provide medical guidance review. “The unique partnership between Genzyme, Project HOPE and the Expert Committee, as well as in-country physicians, brings an otherwise inaccessible, treatment to children and adults afflicted with this devastating disease. Our Committee takes pride in this continuing partnership to improve the health of these patients throughout the world.”

Cerezyme is now available through the Gaucher Initiative to patients living in countries that include Belarus, China, Cuba, Ecuador, Egypt, Haiti, India, Jamaica, Kenya, Pakistan, Palestine, Tanzania, Sri Lanka and Vietnam.

Gaucher disease is one of a group of rare genetic diseases that result from a deficiency in one or more important enzymes in the body. In Type 1 Gaucher disease, the most common form, symptoms include enlargement of the spleen and liver, anemia and bone disease.

### A Dedication to Patients

Genzyme works collaboratively with patient advocacy groups, physicians, non-profit organizations, governments, and others in making therapies available to patients who need them. Genzyme is now developing a program similar to the Gaucher



Initiative for patients with Fabry disease, a genetic disease that is treated through the company's enzyme replacement therapy, Fabrazyme<sup>®</sup> (agalsidase beta).

Genzyme also develops programs for its other products through disease foundations. An example is its work with the American Kidney Fund and Renagel<sup>®</sup> (sevelamer hydrochloride), a therapy to help manage phosphate levels in kidney hemodialysis patients.

### About Project HOPE

Founded in 1958, Project HOPE (Health Opportunities for People Everywhere) is dedicated to providing lasting solutions to health problems, with the mission of helping people help themselves. Identifiable to many by the SS HOPE, the world's first peacetime hospital ship, Project HOPE now conducts land-based medical training and health education programs in 37 countries across five continents. For more information, please visit [www.projecthope.org](http://www.projecthope.org).

### About Genzyme Corporation

Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company's broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services, and sophisticated biomaterials. Genzyme's commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. More than 6,300 Genzyme employees in offices around the globe serve patients in over 80 countries.



This press release contains forward-looking statements, including statements concerning other potential programs to provide patients with access to therapy. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecast in these forward-looking statements. These risks and uncertainties include, among others: the ability to successfully develop, implement and maintain programs with healthcare organizations, patient groups, foundations, or others to provide patients with access to therapy; and the other factors described in Genzyme's periodic filings with the Securities and Exchange Commissions. Please see the disclosure under the heading "Factors Affecting Future Operating Results" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ended March 31, 2004, for a more complete discussion of these and other risk factors. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme<sup>®</sup>, Cerezyme<sup>®</sup>, Fabrazyme<sup>®</sup> and Renagel<sup>®</sup> are registered of Genzyme Corporation. All rights reserved.

# # #

Genzyme's press releases and other company information are available at [www.genzyme.com](http://www.genzyme.com) and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.